Login to Your Account


A new option to treat chronic pain

An open-label phase III study of Egalet Corp.'s abuse-deterrent, extended-release oxycodone, Egalet-002, found the drug to be generally well tolerated by about 150 opioid-experienced patients with moderate-to-severe chronic non-cancer pain.

more »


Opinion


Partners in Focus